<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400504</url>
  </required_header>
  <id_info>
    <org_study_id>TEG-Onkologi</org_study_id>
    <nct_id>NCT00400504</nct_id>
  </id_info>
  <brief_title>Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)</brief_title>
  <official_title>Hypercoagulability and Thromboembolic Risk in Patients With Malignant Disease, Evaluated by Thrombelastograph (TEG®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <brief_summary>
    <textblock>
      Patients with malignancies are at high risk of developing a thromboembolic complication and&#xD;
      their treatment with chemo- and or radiation therapy further enhances this risk.&#xD;
&#xD;
      Conventional haemostatic tests are not suitable as a screening tool of a hypercoagulable&#xD;
      state. A hypercoagulable profile identified with the whole blood Thrombelastograph (TEG)&#xD;
      Analyzer parameter maximal amplitude (MA) is reported to correlate with thrombotic events in&#xD;
      patients undergoing major non-cardial surgery and recurrent ischemic events in patients&#xD;
      undergoing percutaneous coronary intervention.&#xD;
&#xD;
      In this study we investigate the correlation between TEG measurements and thromboembolic&#xD;
      events in patients with newly diagnosed malignancies.&#xD;
&#xD;
      The hypotheses of this study are:&#xD;
&#xD;
        1. Patients with malignancies and hypercoagulability, defined as a TEG MA&gt;69 mm and /or R&lt;4&#xD;
           min is at increased risk of developing thromboembolic complications as compared to those&#xD;
           with a MA&lt;69 mm and/or a R&gt;4 min.&#xD;
&#xD;
        2. Hypercoagulability and hence TEG R and MA values are affected by the treatment&#xD;
           instituted in these patients (chemo and radiation therapy) rendering the patients more&#xD;
           hypercoagulable and hence at increased risk of developing thrombotic complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>500</enrollment>
  <condition>Cancer</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mamma cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pär I Johansson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gedske Daugaard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Louise Bochsen, MSc</last_name>
    <phone>+4535452033</phone>
    <email>louise.bochsen@rh.hosp.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Louise Bochsen, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <last_update_submitted>November 16, 2006</last_update_submitted>
  <last_update_submitted_qc>November 16, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2006</last_update_posted>
  <keyword>Thrombelastograph</keyword>
  <keyword>Cancer</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>Hypercoagulable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

